PMV’s $79.4m cash pile now hinges on rezatapopt’s 2027 ovarian cancer FDA bid
PMV completes key rezatapopt enrollment with a 2027 FDA filing ahead as its $79.4m cash balance exceeds its current market value.
New Alzheimer’s imaging approval could help unlock Lantheus’ neurology merger payouts
TAUKLARIFY wins FDA approval as Lantheus expands its Alzheimer’s imaging franchise ahead of Curium’s $8bn acquisition and neurology CVR targets.
RESTORE trial could turn NVG-291 into NervGen’s defining spinal cord injury asset
NVG-291 heads into Phase 3 as NervGen deploys its $61m cash runway behind a 150-patient test of hand-function recovery in chronic tetraplegia.
Fate Therapeutics bets on outpatient CAR T as FT819 enters potentially registrational study
FT819 enters a potentially registrational lupus nephritis trial with outpatient dosing as Fate tests whether off-the-shelf CAR T can scale.
Sagimet’s acne strategy enters its biggest test after FDA clears denifanstat Phase 3
FDA clearance sends denifanstat into an 800-patient U.S. Phase 3 as Sagimet deploys its $257.6m cash base. See what the pivotal test means.
Mapi Pharma targets cariprazine lifecycle extension with once-monthly injectable
Mapi’s monthly Cariprazine Depot clears its first safety hurdle as a $3.6bn oral franchise approaches a key 2029 patent transition.
Luigi Mangione admits shooting UnitedHealthcare CEO as federal case ends without trial
Luigi Mangione admits killing Brian Thompson and pleads guilty federally as a new double-jeopardy fight threatens his New York murder trial.
Can a nasal therapy bypass the blood-brain barrier? NEO100’s Phase 2a data offer an early answer
NEO100 posts 48.9% six-month PFS and 26-month median survival, but NeOnc’s $2m cash balance puts funding and FDA strategy in focus.
Intermex stock jumps 23% as Western Union acquisition moves closer despite California setback
Intermex shares surged 23% as Western Union won New York approval for its $500M takeover, but a fresh California review keeps risk alive.
White House ballroom battle reaches Supreme Court as Trump invokes national security
Trump takes his $400 million White House ballroom fight to the Supreme Court, raising major questions over presidential power and Congress.